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Background: To study hormonal changes associated with severe hyperglycemia in critically ill children and the
relationship with prognosis and length of stay in intensive care.
Methods: Observational study in twenty-nine critically ill children with severe hyperglycemia defined as 2 blood
glucose measurements greater than 180 mg/dL. Severity of illness was assessed using pediatric index of mortality
(PIM2), pediatric risk of mortality (PRISM) score, and pediatric logistic organ dysfunction (PELOD) scales. Blood glucose,
glycosuria, insulin, C-peptide, cortisol, corticotropin, insulinlike growth factor-1, growth hormone, thyrotropin, thyroxine,
and treatment with insulin were recorded. β-cell function and insulin sensitivity and resistance were determined on the
basis of the homeostatic model assessment (HOMA), using blood glucose and C-peptide levels.
Results: The initial blood glucose level was 249 mg/dL and fell gradually to 125 mg/dL at 72 hours. Initial β-cell
function (49.2%) and insulin sensitivity (13.2%) were low. At the time of diagnosis of hyperglycemia, 50% of the
patients presented insulin resistance and β-cell dysfunction, 46% presented isolated insulin resistance, and 4%
isolated β-cell dysfunction. β-cell function improved rapidly but insulin resistance persisted. Initial glycemia did
not correlate with any other factor, and there was no relationship between glycemia and mortality. Patients who
died had higher cortisol and growth hormone levels at diagnosis. Length of stay was correlated by univariate
analysis, but not by multivariate analysis, with C-peptide and glycemic control at 24 hours, insulin resistance, and
severity of illness scores.
Conclusions: Critically ill children with severe hyperglycemia initially present decreased β-cell function and
insulin sensitivity. Nonsurvivors had higher cortisol and growth hormone levels and developed hyperglycemia
later than survivors.
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The incidence of hyperglycemia is very high, between 56
and 86%, and it is an independent risk factor for morbidity
and mortality in critically ill patients [1-3].
Many studies have analyzed the effect of treatment of
hyperglycemia on the prognosis of critically ill patients.
Although initial studies found that intensive insulin
treatment improved the prognosis, subsequent research
has not confirmed these findings and has detected a
higher incidence of hypoglycemia [1-7].
Few studies have investigated the pathophysiological
mechanisms involved in hyperglycemia of the critically
ill patient [8-11]. Hyperglycemia of critically ill adults
and children have different characteristics. An under-
standing of the mechanisms that give rise to hypergly-
cemia in the critically ill child could help to define the
most appropriate treatment.
The objectives of the present study were to investigate
the pathophysiological mechanisms of severe hypergly-
cemia in the critically ill child, to analyze the clinical
factors associated with hyperglycemia, and to evaluate
the association of hyperglycemia with prognosis and length
of hospital stay.
Methods
A prospective observational study was performed in
patients aged between 1 month and 16 years admitted to
the Pediatric Intensive Care Unit (PICU) between July
2009 and March 2010 and who developed significant
hyperglycemia, defined as 2 blood glucose measurements
greater than 180 mg/dL, separated by at least 2 hours, at
any time during admission to the PICU. Children with
type 1 diabetes mellitus were excluded from the study.
The study was approved by the Investigation and Ethics
Committee of the Gregorio Marañón Hospital. Parents or
legal guardians gave their parental permission for the child
to participate in the study and to publish the results.
Clinical severity was assessed using the pediatric index
of mortality 2 (PIM2) [12], pediatric risk of mortality
(PRISM) score [13], and pediatric logistic organ dys-
function (PELOD) scale [14]. PIM score calculates the
risk of mortality based in the first clinical and analytical
data after admission. They include the kind of admission
(programmed or no), the diagnosis classified in high and
low-risk, photomotor reflex, mechanical ventilation,
blood pressure, base deficit and FiO2/PaO2 [12]. PRISM
score calculates the risk of mortality based on the worst
values in the first 24 h of admission of several physiological
values (heart rate, blood pressure, Glasgow scale and
pupillary reaction) and analytical values (PaO2/FiO2,
PaCO2, prothrombine time, billirubin, calcium, potassium,
glycemia) [13]. PELOD score evaluates the risk of mortality
analyzing the number of failure of different systems by
different parameters: cardiovascular (heart rate, bloodpressure), respiratory (PaO2/FiO2, PaCO2, mechanical
ventilation), neurologic (Glasgow score, pupillary reactions),
hematologic (leucocytes, platelets), renal (creatinine),
hepatic (AST, prothrombine time). Scores was recorded at
the time of diagnosis of hyperglycemia and 24 and 72 hours
later. Treatment with corticosteroids, the doses of vaso-
active drugs, the vasoactive score calculated by the follow-
ing formula: dopamine dose (μg/kg/min) + dobutamine
dose (μg/kg/min) + 100 epinephrine dose (μg/kg/min) + 10
milrinone dose (μg/kg/min) + 10.000 vasopresine dose
(U/kg/min) + 100 noerpinephrine dose (μg/kg/min) [15],
blood glucose, glycosuria, insulin, C-peptide, cortisol,
corticotropin (ACTH), insulinlike growth factor (IGF-1),
growth hormone (GH), thyrotropin (TSH), free thyroxine
(T4), and dose of insulin treatment were recorded at
the time of diagnosis of hyperglycemia and 24 and
72 hours later.
Insulin, C-peptide, cortisol, and IGF-1 were measured
using a solid-phase chemoluminescent enzyme immuno-
metric assay (Immulite 2000, Siemens), ACTH and GH
using an immunoradiometric assay (DiaSorin), TSH
using a solid-phase paramagnetic-particle chemolumi-
nescent enzyme immunometric assay (Access®Beckman
Coulter™), and free T4 using a 2-step, paramagnetic-particle
competitive chemoluminescent enzyme immunoassay
(Access®Beckman Coulter™).
β-cell function and insulin sensitivity and resistance
were determined on the basis of the homeostatic model
assessment (HOMA) calculated by computer software
(www.OCDEM.ox.ac.uk) [16,17]. HOMA model is used
to estimate insulin sensitivity (HOMA-%S) and β-cell
function (HOMA-%B) using blood glucose and C-peptide
levels [16]. Normal β-cell function is a HOMA-%B of
100%, normal insulin sensitivity is a HOMA-%S of 100%,
and normal insulin resistance is 1 [16].
In accordance with our protocol, insulin was admin-
istered to those patients who presented blood glycemia
above 200 mg/dL in 2 measurements separated by 4 hours.
Treatment was started with 0.05-0.1 IU/kg/h, with hourly
monitoring of the glycemia and glycosuria and adjustment
of the insulin infusion to achieve glycemia between 120
and 150 mg/dL; subsequent monitoring was performed at
least every 4 hours and the insulin infusion was inter-
rupted if the glycemia fell below 120 mg/dl. The dose and
duration of insulin treatment and the adverse effects
attributable to treatment were recorded. Hypoglycemia
was defined as glycemia less than 60 mg/dL.
The presence of infection, the need for and duration
of mechanical ventilation, continuous renal replacement
therapy (CRRT), and extracorporeal membrane oxygen-
ation (ECMO), the duration of PICU admission, and
mortality and its causes were also recorded.
Statistical analysis of the results was performed with the
SPSS statistical package, version 18. The nonparametric
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used to compare quantitative variables, the Pearson χ2 test
was used to compare frequencies, and the nonparametric
Spearman rank correlation (ρ) was used to determine the
correlation between quantitative variables. A P value less
than .05 was considered significant. Multiple logistic regres-
sion analysis was made to study the association of variables
with length of PICU admission and mortality.
Results
Characteristics of patients
Thirty-one hyperglycemic episodes were detected in 29
patients (2 patients presented 2 episodes separated by
more than 7 days), aged between 1 and 204 months
(median, 36 months) and weighing between 4 and 70 kg
(median, 16.3 kg).
The reasons for admission were the following: post-
operative period of cardiac surgery in 22, postoperative
period of colectomy for ulcerative colitis in 1, cardiogenic
shock in 4 and respiratory disease in 2.
Mechanical ventilation was required by 74% of patients,
ECMO by 41%, and renal replacement therapy by 41% dur-
ing admission to the PICU, and 48% developed nosocomial
infection (respiratory tract in 24%, sepsis in 17%, and other
sites in 6%). 96.5% of patients received vasoactive drugs
(initial vasoactive score was 3.5 (IQR 3–5) and it did not
change during the study. Four patients (13%) died during
admission to the PICU, 3 due to multiorgan failure and 1
due to cerebral hemorrhage.
Initially all patients received intravenous glucose infu-
sion and during the study enteral nutrition was started and
increased progressively. Carbohydrate delivery is showed in
Table 1. None of patients received parenteral nutrition.
Evolution of blood glucose and hormone levels
The changes in the blood glucose, hormone levels, clinical
severity scores, and clinical parameters over the 72 hours
of the study are shown in Table 1. The median initial
blood glucose was 249 mg/dL, and this fell significantly
to reach values of 125 mg/dL at 72 hours, despite a
progressive increase in carbohydrate ingestion (Table 1).
Intravenous insulin treatment was required in 83% of
the episodes (mean dose, 0.11 ± 0.09 U/kg/h; mean dur-
ation of treatment, 45.2 ± 74.6 hours). The minimum
blood glucose was 74 mg/dL. None of the patients de-
veloped hypoglycemia.
The insulin and C-peptide levels were elevated initially
in 64% and 72% of patients, respectively, and did not show
significant variations over the 72 hours of the study. β-cell
function and insulin sensitivity were initially low but in-
creased over the first 24 hours, although only the change
in β-cell function reached statistical significance.
At the time of diagnosis of hyperglycemia, 50% of the pa-
tients presented insulin resistance and β-cell dysfunction,46% presented isolated insulin resistance, and 4% isolated
β-cell dysfunction.
Cortisol levels were initially elevated (levels above
25 μg/dL in 64% of patients), though ACTH levels
were normal. During the course of the study, there was
a significant fall in cortisol levels but no change in
ACTH. Patients did not received steroids during the
three days of the study. 15 patients received steroids
previously to the diagnosed of hyperglycemia. There
were no significant differences in initial cortisol levels
of patients treated with steroids (47.3 μg/dL) than of
the rest of patients (57.9 μg/dL).
T4 levels were initially normal, whereas 44% of patients
presented low TSH levels. Over the course of the study
there was a significant fall in T4 (36% of patients had low
T4 levels at 72 hours), though there were no significant
changes in TSH levels.
The levels of GH and IGF-1 were initially low and there
were no significant changes over the course of the study.
Correlation between parameters
No relationship was observed between the blood glucose
at any time during the evolution and most of hormone
parameters, clinical variables, and treatments. Nor were
there differences in the changes in blood glucose over
the course of the study according to age, sex, diagnosis,
need for mechanical ventilation, ECMO or CRRT, or the
presence of nosocomial infection.
Only at 24 and 72 hours there was a significant
correlation between the blood glucose and insulin and
C-peptide levels and between these 3 parameters and
the PRIMS, PIM2, and PELOD clinical severity scores
(data not showed). There was a relationship between
the maximum blood glucose and the maximum dose of
insulin administered (ρ = 0.596, P = .001), but not with
the duration of insulin treatment.
Correlation with prognosis
There was no relationship between glucose levels over
the course of the study and mortality. However, the
onset of hyperglycemia occurred later in nonsurvivors
than in survivors. The following factors were associated
with mortality: cardiogenic shock (P = .014), nosocomial
infection (P = .008), and the need for ECMO (P < .001)
or CRRT (P < .001). Compared to survivors, patients who
died had higher cortisol levels at the time of diagnosis of
hyperglycemia and 24 hours later. GH values at the time
of diagnosis of hyperglycemia were also higher in the
patients who died. Compared to survivors, patients who
died presented greater insulin resistance 72 hours after
diagnosis (Table 2). There was no relationship between
mortality and the values of the other hormones. Multiple
logistic regression analysis could not be performed because
only four patients died.
Table 1 Changes in hormone levels and clinical parameters
At diagnosis of hyperglycemia At 24 hours At 72 hours P
Median (IQR) Median (IQR) Median (IQR)
Blood glucose, mg/dl 249 217-315 153 112-194 125 109-166 0.0001
Insulinemia, mUI/L 20 8.5-32.5 13 6.5-27.5 16 7-29 0.401
C-peptide, nmol/L 2 0.8-2.7 1.6 1-2.6 2 0.9-3.9 0.903
β-cell function with C-peptide % 49.2 30.8-91.3 96.3 78.4-139.8 135.9 95.2-187.8 0.001
Insulin sensitivity % with C-peptide 13.2 10.3-32.2 21.9 11.9-33.0 20.6 11.9-38.7 0.085
Insulin resistance with C-peptide 7.6 3.1 -9.6 4.5 3-8.4 4.9 2.7-8.3 0.081
Carbohydrate delivery, g/kg/day 2 1.8 -4.4 4.8 1.9-8.5 7.3 4.8-9.2 0.001
TSH, mUI/L 0.5 0.3-0.8 0.3 0.2-0.9 0.6 0.2-3.3 0.091
Free T4, ng/dL 1 0.8-1.2 0.9 0.7-1.2 0.7 0.5-1.2 0.009
ACTH, ng/L 21.5 12.8-41 21 12-33.5 20.8 11.6-34.4 0.410
Cortisol, μg/dL 43.7 12.6-77.3 16.1 7.9 -30.1 15.5 8.9-34.9 0.001
GH, μg/L 0.8 0.5-7.1 1.2 0.5-2.9 1.8 0.6-3.4 0.708
IGF1, μg/L 26 25-89. 25 25-54 25 25-48 0.132
PRIMS % 15.6 5.7-42.5 13.2 4.2-33.6 7.5 1.4-29.2 0.349
PIM2 % 2.7 1.4-11.8 3.4 2-18.9 5.4 0.5-25.2 0.397
PELOD % 6.7 1-19.5 1.5 0.1-1.7 1.3 0-2.3 0.787
HR, bpm 125 113.7-150.2 130 112.5-150 127.5 110-148.5 0.482
MAP, mmHg 62 55.5-72.2 67 54.5-73.5 63 58-79.5 0.837
Abbreviations: ACTH corticotrophin, bpm beats per minute, GH growth hormone, HR heart rate, IGF insulinlike growth factor, IQR interquartile range, MAP mean
arterial pressure, PELOD pediatric logistic organ dysfunction, PIM2 pediatric index of mortality 2, PRIMS pediatric risk of mortality, T4 thyroxine, TSH thyrotropin.
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Length of stay was associated with the severity of illness
scores, the blood glucose, C-peptide levels, insulinemia
(Table 3), the time from admission to the onset of hypergly-
cemia (r = 0.532, p = 0.002), the maximum dose of insulin
(r = 0.539, p = 0.004), and the duration of treatment withTable 2 Comparison between survivors and nonsurvivors
Survivors Nonsurvivors P
Median (IQR) Median (IQR)
Onset of
hyperglycemia, h
6.5 (3.7 -27) 59 (13.5-137.5) .028
Baseline cortisol, μg/dL 37 (12.4-66) 100 (74–138) .024
Cortisol at 24 h, μg/dL 13 (5.6 -22.4) 39.7 (29.9-59.3) .003
Baseline GH, μg/dL 0.7 (0.5-3.6) 15 (1.8-31) .026
Sensitivity with
C-peptide at 72 h, %
29.0 (14.3-67.8) 11.9 (10.7-12.9) .026
IR with C-peptide
at 72 h
3.4 (1.5-6.9) 8.4 (7.7 -9.3) .026
Cardiogenic shock 7.3% 60% .014
Nosocomial infection 30.7% 100% .008
ECMO 0% 100% .001
CRRT 0% 100% .001
Abbreviations: CCRT continuous renal replacement therapy, ECMO
extracorporeal membrane oxygenation, GH growth hormone, IR insulin
resistance, IQR interquartile range.insulin (r = 0.602, p = 0.001). There were also statistically
significant correlations between the length of PICU stay
and the presence of nosocomial infection (P = .001) or the
need for ECMO (P = .012), CRRT (P = .012), or mechanical
ventilation (P = .001).
Multiple logistic regression analysis did not identify
factors associated with a length of PICU stay more than
14 days, possibly due to the low number of patients
studied. The univariate and multivariate analyses of the
patients in the postoperative period of cardiac surgery
did not show different results than analysis of the total
population (data not shown).
Discussion
Critical illness hyperglycemia (CIH) is probably due to
endogenous counter-regulatory hormones and other
diabetogenic factors, such as proinflammatory media-
tors and therapeutic interventions, including the ad-
ministration of glucocorticoids and catecholamines,
which interfere with insulin-receptor signaling and/or
glucose transport and utilization within cells [8-11,18-21].
On the other hand insulin therapy acts to suppress
counterregulatory hormones and proinflammatory tran-
scription factors.
Our study is the first to analyze the relationship of severe
hyperglycemia in the critically ill child with the values of
various hormones and with the clinical course.
Table 3 Correlation between length of pediatric intensive care stay and other variables
Time of diagnosis of hyperglycemia 24 h after the diagnosis 72 h after diagnosis
Correlation (r) P Correlation (r) P Correlation (r) P
PRIMS 0.508 0.060 0.480 0.037
PIM2 0.568 0.004 0.626 0.001 0.548 0.015
PELOD 0.499 0.013 0.497 0.007 0.615 0.005
MAP −0.429 0.018 −0.515 0.020
Blood glucose 0.531 0.004
C-peptide 0.697 0.001 0.618 0.002
Insulinemia 0.542 0.030
IGF-1 −0.500 0.011 −0.393 0.043
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relationship with hormonal alterations
Hyperglycemia is a state of metabolic dysregulation due
to an imbalance between insulin production and insulin
sensitivity in the target tissues [8].
C-peptide and insulin levels
Studies in adults suggest that CIH is primarily due to insu-
lin resistance in spite of a situation of supranormal β-cell
function, because beta cell could not secrete as much
insulin as that necessary to compensate insulin resistance
[17,22]. However, in CIH in children, the C-peptide levels
may be low or elevated [8]. Our patients presented elevated
C-peptide levels, although these levels were relatively low
given the blood glucose levels at that time, which would
suggest the presence both of reduced β-cell function and
of increased insulin resistance.
Preissig et al., found in 41 critically ill children with
hyperglycemia, that low levels of insulin were associated
with a rapid onset of hyperglycemia, greater clinical sever-
ity, greater insulin requirements and increased duration of
mechanical ventilation and length of PICU stay [8]. We
found higher C-peptide levels in more severely ill patients
(higher PRISM, PIM2, and PELOD scores) and that higher
C-peptide levels were associated with a longer PICU stay,
probably because C-peptide levels were a marker of more
severe ill. In contrast to the findings of Preissig et al., in
our study the onset of hyperglycemia occurred later in the
more seriously ill patients.
In a study of children with meningococcal sepsis and
hyperglycemia 62% presented isolated insulin resistance,
17% β-cell dysfunction and 21% combined β-cell dysfunc-
tion and insulin resistance [17]. In our patients, there was
a reduction both in β-cell function and in insulin sensitiv-
ity at the time of diagnosis of the hyperglycemia. Both
improved at 24 hours and β-cell function normalized at
72 hours, though a degree of insulin resistance persisted.
This would suggest that the mechanism of hyperglycemia
in critically ill children with severe hyperglycemia is prob-
ably multifactorial and involve both a relative reduction ininsulin production due to beta cell dysfunction whose
cause of the is not well known, and peripheral resist-
ance to insulin.
It has been reported that treatment with exogenous
insulin improves insulin sensitivity [23]. In our study
there was a slight improvement in insulin sensitivity at
24 hours, coinciding with insulin treatment, though
sensitivity continued to be low at 72 hours.
Inotropic index
Catecholamines may directly suppress β-cell function
and insulin secretion [8]. Some authors have reported that
the inotropic index is inversely related to C-peptide levels
and that hyperglycemic children have a higher inotropic
index [18]. In contrast, other authors have found no cor-
relation between the inotropic index and blood glucose,
insulin or C-peptide levels [17], as occurred in our study.
Corticosteroids
Corticotropin-releasing hormone and ACTH control corti-
sol secretion in the acute phase of critical illness, whereas
non-ACTH-mediated pathways (interleukin [IL] 1, IL6, and
tumor necrosis factor-α) are involved during prolonged
critical illness. Protracted critical illness is associated with a
fall in plasma ACTH concentrations despite the persistence
of a state of hypercortisolism [24].
Our results, with very high initial cortisol levels, co-
incide with previous reports. The absence of elevated
ACTH levels suggests that other factors contributed to
the hypercortisolism in the majority of our patients.
We found no relationship between cortisol and blood
glucose levels at any time. We cannot therefore state
that corticosteroids played a fundamental role in the
onset of hyperglycemia in our patients.
Growth hormone and insulinlike growth factor-1
GH secretion is induced by stress and the mean serum
GH level may be elevated early in the course of trauma
or surgery and fall progressively during the first week [25].
Serum IGF-1 levels are almost invariably low in critically
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presence of enhanced GH secretion indicates GH resist-
ance [25]. In our study, GH and IGF-1 levels were initially
low and they showed no significant modifications over the
course of the study. There was no relationship of the GH
and IGF-1 levels with blood glucose, insulin, or C-peptide
levels, suggesting that these hormones do not play a role
in the onset of hyperglycemia.
Thyrotropin and thyroxine
In critically ill patients, T3 is typically low on admission,
with normal or slightly elevated TSH and T4 levels. TSH
levels subsequently normalize while T3 levels remain low
and, in serious diseases such as meningococcal sepsis,
T4 levels fall [26]. In our study, a large proportion of
the children had low TSH levels at the time of diagnosis
of hyperglycemia, with normal T4 values. However, T4
levels fell progressively, probably reflecting the severity of
the illness. We are therefore unable to state that there is a
clear link between thyroid hormone alterations and the
onset of hyperglycemia.
Relationship of blood glucose levels and treatment
with prognosis
Most studies have reported that hyperglycemia occurs
early in critical illness and is independently associated
with death [1,2,18,19]. However, it is unclear whether this
association is indicative of the severity of the underlying
illness or that hyperglycemia is itself a risk factor. Other
studies in critically ill children have found no association
between the blood glucose levels and mortality [27] or
length PICU stay [20].
Our study showed that children with persistent severe
hyperglycemia had a high mortality (13%)—the overall
mortality in our PICU over the study period was 3%. This
fact suggest that hyperglycemia is a marker of severity and
an indicator of risk of death [28]. However, although the
number of patients was low, we did not find a relationship
between the absolute blood glucose, C-peptide, or insulin
values and mortality. The presence of hyperglycemia would
therefore appear to be a marker of severity in the critically
ill patient but not itself worsen the prognosis.
On the other hand, we found that the onset of hypergly-
cemia occurred later in patients that died than in survivors
and nonsurvivors presented greater insulin resistance at
72 hours after diagnosis. This could indicate the existence
of two types of hyperglycemia in the critically ill patient. An
initial, frequently transitory hyperglycemia caused by the
stress of admission to the PICU and that is not associated
with a poor prognosis, and another of later onset that could
reflect more serious metabolic dysregulation with persistent
insulin resistance and that is an indicator of mortality.
In our study, the main factors associated with mortal-
ity and the length of PICU stay were the clinical severityscores and the presence of severe multiorgan failure with
the need for CRRT and ECMO.
Initial studies in critically ill patients found short-term
benefits to maintaining normoglycemia [1,29]. However
recent studies have found that intensive treatment with in-
sulin does not decrease mortality [6,7,30] and may even
be associated with a higher mortality and hypoglycemia
[6,7,27,29]. A large proportion of our patients received in-
sulin treatment despite our use of more restrictive indica-
tions for insulin treatment and less strict glycemic control
objectives. None of our patients developed hypoglycemia,
which confirms that insulin treatment with moderate ob-
jectives reduces the risk of hypoglycemia.
Corticosteroids and prognosis
The higher corticosteroids levels in the patients who
died support the hypothesis that these patients had more
serious illness and therefore had a more marked adrenal
response. Many studies have analyzed the relationship of
corticosteroid levels and the adrenal response with the
prognosis of septic patients, reporting contradictory results
[31,32]. The data from our study only allow us to state that
critically ill children with hyperglycemia very often present
elevated corticosteroid levels and that patients who die have
higher levels than survivors. In critically ill children, both
low and elevated corticosteroid levels may be indicators of
severity and of risk of death. However, the number of pa-
tients who died in our study was small and further studies
are necessary to confirm these results.
Limitations
Our study has certain limitations. The number of patients
was low and most of them were in the postoperative
period of cardiac surgery. The number of patients could
not permit to perform a multiple logistic regression ana-
lysis and it is a small sample size to detect a difference
in mortality. There was no control group without hyper-
glycemia to compare hormonal changes. However it is
very difficult to achieve a control group with the same
characteristics and severity as the study group but with-
out hyperglycemia. To use HOMA in critically ill pa-
tients in those glucose and insulin concentrations are
not in a steady state and/or are receiving exogenous in-
sulin has limitations because this method has not been
verified in these situations and for this reason the inter-
pretation of the results has to be made with caution.
The duration of the study was limited, as patients were
only studied for 72 hours and we therefore do not know
the changes in the hormone levels over the subsequent
days, although the majority of the patients achieved ad-
equate glycemic control at 72 hours. PRISM and PIM
was measured to evaluate the severity of illness at differ-
ent times although these scores only have been validated
in the first 24 hours of admission. Analytical measures
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the day and this fact could influence in some hormone
values as ACTH or cortisol. Finally, we did not measure
other factors that could mediate in the onset of hypergly-
cemia in the critically ill patient, such as catecholamines,
cytokines, glucagonlike peptide-1 or nonesterified fatty
acids [33].
Conclusions
We conclude that critically ill children with severe hyper-
glycemia initially have reduced β-cell function and insulin
sensitivity. β-cell function recovers rapidly but peripheral
resistance to insulin persists. There was no relationship be-
tween glycemia and the majority of the hormonal changes
detected. Patients who died had higher cortisol and growth
hormone levels and developed hyperglycemia later than
survivors. There was no relationship between glycemia and
mortality although the number of patients is too small
to detect differences. Length of stay was associated with
C-peptide, insulin, and blood glucose levels, insulin resist-
ance, and severity of illness at 24 hours.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors have made substantial contributions to conception and design,
or acquisition of data, or analysis and interpretation of data; have been
involved in drafting the manuscript or revising it critically for important
intellectual content; and have given final approval of the version to be
published. YB and JL-H: conceived the study and participated in the design,
data collection and analysis, and drafting of the manuscript. RG, MJS, JC, JU,
MB, and AGS participated in the design of the study, data collection and
analysis of data, and drafting of the manuscript. NL performed hormonal
laboratory analysis and drafted the manuscript. JMB participated in the
design of the study and performed the statistical analysis. All authors read
and approved the final manuscript.
Acknowledgements
To the nurses of the Pediatric Intensive Care Department of the Hospital
Gregorio Marañón for their contribution to this study.
Author details
1Pediatric Intensive Care Department, Hospital General Universitario Gregorio
Marañón Complutense University of Madrid, Madrid, Spain. 2Laboratory
Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
3Instituto de Investigación biomédica del Hospital Gregorio Marañón, Madrid,
Spain. 4Red de Salud Materno Infantil y del Desarrollo, Red SAMID II, Madrid,
Spain.
Received: 6 October 2013 Accepted: 11 March 2014
Published: 14 March 2014
References
1. Vlasselaers D, Milants I, Desmet L, Wouters PJ, Vanhorebeek I, van den
Heuvel I, Mesotten D, Casaer MP, Meyfroidt G, Ingels C, Muller J, Van
Cromphaut S, Schetz M, Van den Berghe G: Intensive insulin therapy for
patients in paediatric intensive care: a prospective, randomised
controlled study. Lancet 2009, 373:547–556.
2. Yung M, Wilkins B, Norton L, Slater A: Glucose control, organ failure, and
mortality in pediatric intensive care. Pediatr Crit Care Med 2008, 9:147–152.
3. Hirshberg E, Larsen G, Van Duker H: Alterations in glucose homeostasis in
the pediatric intensive care unit: Hyperglycemia and glucose variability
are associated with increased mortality and morbidity. Pediatr Crit Care
Med 2008, 9:361–366.4. The NICE-SUGAR Study Investigators: Intensive versus conventional
glucose control in critically ill patients. N Engl J Med 2009, 360:1283–1297.
5. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz
M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin
therapy in the critically ill patients. N Engl J Med 2001, 345:1359–1367.
6. Agus MS, Steil GM, Wypij D, Costello JM, Laussen PC, Langer M, Alexander
JL, Scoppettuolo LA, Pigula FA, Charpie JR, Ohye RG, Gaies MG, SPECS Study
Investigators: Tight glycemic control versus standard care after pediatric
cardiac surgery. N Engl J Med 2012, 367:1208–1219.
7. Macrae D, Grieve R, Allen E, Sadique Z, Morris K, Pappachan J, Parslow R,
Tasker RC, Elbourne D, CHiP Investigators: A randomized trial of hyperglycemic
control in pediatric intensive care. N Engl J Med 2014, 370:107–118.
8. Preissig CM, Rigby MR: Hyperglycaemia results from beta-cell dysfunction
in critically ill children with respiratory and cardiovascular failure:
a prospective observational study. Crit Care 2009, 13:R27.
9. Vasa FR, Molitch ME: Endocrine problems in the chronically critically ill
patient. Clin Chest Med 2001, 22:193–208.
10. Delarue J, Magnan C: Free fatty acids and insulin resistance. Curr Opin Clin
Nutr Metab Care 2007, 10:142–148.
11. Mesotten D, Swinnen JV, Vanderhoydonc F, Wouters PJ, Van der Berghe G:
Contribution of circulating lipids to the improved outcome of critical
illness by glycemic control with intensive insulin therapy. J Clin
Endocrinol Metab 2004, 89:219–226.
12. Slater A, Shann F, Pearson G: PIM II. A revised version of the Paediatric
Index of Mortality. Intensive Care Med 2003, 29:278–285.
13. Pollack MM, Ruttimann UE, Getson PR: The pediatric risk of mortality
(PRISM) score. Crit Care Med 1988, 16:1110–1116.
14. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J,
Gottesman R, Joffe A, Pfenninger J, Hubert P, Lacroix J, Leclerc F: Validation
of pediatric logistic organ dysfunction (PELOD) score. Prospective,
observational, multicenter study. Lancet 2003, 362:192–197.
15. Haterill M, Tibby SM, Hillirad T, Turner C, Murdoch IA: Adrenal insufficiency
in septic shock. Arch Dis Child 1999, 80:51–55.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC:
Homeostasis model assessment: insulin resistance and β-cell function
from fasting plasma glucose and insulin concentrations in man.
Diabetologia 1985, 28:412–419.
17. Verhoeven JJ, den Brinker M, Hokken-Koelega AC, Hazelzet JA, Joosten KF:
Pathophysiological aspects of hyperglycemia in children with meningococcal
sepsis and septic shock: a prospective, observational cohort study. Crit Care
2011, 15:R44.
18. Preissig CM, Rigby MR, Maher KO: Glycemic control for postoperative
pediatric cardiac patients. Pediatr Cardiol 2009, 30:1098–1104.
19. Faustino EV, Bogue CW: Relationship between hypoglycemia and
mortality in critically ill children. Pediatr Crit Care Med 2010, 11:690–698.
20. Branco RG, Tasker RC: Glycemic level in mechanically ventilated children
with bronchiolitis. Pediatr Crit Care Med 2007, 8:546–550.
21. Allen HF, Rake A, Roy M, Brenner D, McKiernan CA: Prospective detection
of hyperglycemia in critically ill children using continuous glucose
monitoring. Pediatr Crit Care Med 2008, 9:153–158.
22. Soop M: Stress induced insulin resistance: recent developments. Curr Opin
Clin Nutr Metab Care 2007, 10:181–186.
23. Fram RY, Cree MG, Wolfe RR, Mlcak RP, Qian T, Chinkes DL, Herndon DN:
Intensive insulin therapy improves insulin sensitivity and mitochondrial
function in severely burned children. Crit Care Med 2010, 38:1475–1483.
24. Arafah BM: Review: Hypothalamic pituitary adrenal function during
critical illness: limitations of current assessments methods. J Clin
Endocrinol Metab 2006, 91:3725–3745.
25. Baxter RC: Changes in the IGF-IGFBP axis in critical illness. Best Pract Res
Clin Endocrinol Metab 2001, 15:421–434.
26. Mebis L, van den Berghe G: The hypothalamus-pituitary-thyroid axis in
critical illness. Neth J Med 2009, 67:332–340.
27. Garcia Branco R, Xabier L, Celiny P, Piva JP, Fiori HH, Baldisserotto M, Fiori
RM, Tasker RC: Prospective operationalization and feasibility of a
glycemic control protocol in critically ill children. Pediatr Crit Care Med
2011, 12:265–270.
28. Bhutia TD, Lodha R, Kabra SK: Abnormalities in glucose homeostasis in
critically Ill children. Pediatr Crit Care Med 2012. Epub ahead of print.
29. Rake AJ, Srinivasan V, Nadkarni V, Kaptan R, Newth CJ: Glucose variability
and survival in critically ill children: allostasis or harm? Pediatr Crit Care
Med 2010, 11:707–712.
Ballestero et al. BMC Endocrine Disorders 2014, 14:25 Page 8 of 8
http://www.biomedcentral.com/1472-6823/14/2530. Treggiari MM, Karir V, Yanez ND, Weiss NS, Daniel S, Deem SA: Intensive
insulin therapy and mortality in critically ill patients. Crit Care 2008, 12:R29.
31. Hebbar KB, Stockwell JA, Leong T, Fortenberry JD: Incidence of adrenal
insufficiency and impact of corticosteroid supplementation in critically ill
children with systemic inflammatory syndrome and vasopressor-dependent
shock. Crit Care Med 2011, 39:1145–1150.
32. COIITSS Study Investigators, Annane D, Cariou A, Maxime V, Azoulay E,
D’honneur G, Timsit JF, Cohen Y, Wolf M, Fartoukh M, Adrie C, Santré C,
Bollaert PE, Mathonet A, Amathieu R, Tabah A, Clec’h C, Mayaux J, Lejeune J,
Chevret S: Corticosteroid treatment and intensive insulin therapy for
septic shock in adults: a randomized controlled trial. JAMA 2010,
303:341–348.
33. Mechanick JI: Metabolic mechanisms of stress hyperglycemia. J Parenter
Enteral Nutr 2006, 30:157–163.
doi:10.1186/1472-6823-14-25
Cite this article as: Ballestero et al.: Relationship between hyperglycemia,
hormone disturbances, and clinical evolution in severely hyperglycemic
post surgery critically ill children: an observational study. BMC Endocrine
Disorders 2014 14:25.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
